Dementia - Articles - Page 2 | CARLAT PUBLISHING

Fact Sheet

Dementia with Lewy Bodies: Treatment

August 2, 2025

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by the presence of Lewy bodies in the brain.

Fact Sheet

Dementia with Lewy Bodies: Diagnosis

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lewy Body Dementia (LBD) is a progressive neurodegenerative disorder.

Fact Sheet

Alzheimer’s Dementia: Stages and Treatment

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Alzheimer’s Dementia (AD) is a progressive neurodegenerative disorder that primarily impacts older adults.

Fact Sheet

Alzheimer’s Dementia: Diagnosis and Evaluation

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Alzheimer’s Dementia (AD) is the most common type of dementia, comprising about 60%–70% of all dementia cases and impacting 6.2 million Americans over age 65.

Expert Q&A

Pharmacotherapy for Dementia

March 1, 2025

Stephanie Collier, MD

Director of Education in the Division of Geriatric Psychiatry at McLean Hospital and an instructor in psychiatry at Harvard Medical School. Editor-in-Chief, The Carlat Geriatric Psychiatry Report.

Dr. Collier has no financial relationships with companies related to this material.

We have three newly approved meds for dementia. Brexpiprazole (Rexulti) for agitation, and donanemab (Kisunla) and lecanemab (Leqembi) for the core features of Alzheimer’s. Dr. Collier explains why none of these are first-line.

Research Update

Which Leisure Activities Can Lower Dementia Risk?

January 1, 2025

Paroma Mitra, MD.

Paroma Mitra, MD. Dr. Mitra has served as a consultant for Bristol Meyers Squibb. Relevant financial relationships listed for the author have been mitigated.

Can the way you spend your free time protect your brain? New findings suggest leisure activities may reduce the risk of developing dementia.

Expert Q&A

Disparities in Dementia Diagnosis

October 1, 2024

Nicolás Pérez Palmer, MD

Nicolás Pérez Palmer, MD

Assistant Professor of Psychiatry, Yale School of Medicine, New Haven, CT; Director of Clinical Research Services, Latino Community, Alzheimer’s Disease Research Unit; Integrated Firm Director, Psychiatry, VA Connecticut Healthcare System.

Dr. Pérez Palmer has no financial relationships with companies related to this material.

Dr. Pérez Palmer explores health disparities in geriatric psychiatry, focusing on how social determinants affect dementia diagnosis and treatment among underrepresented populations, while addressing strategies to improve equitable care for older adults.

Research Update

Smartphone Apps Benefit Memory and Quality of Life

July 1, 2024

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.

This trial tests whether mobile apps improve prospective memory in MCI.

Expert Q&A

Treatment Challenges in Atypical Parkinsonism

July 1, 2024

Alice Flaherty, MD, PhD

Alice Flaherty, MD, PhD.

Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.

Dr. Flaherty has no financial relationships with companies related to this material.

Patients with atypical parkinsonism are less responsive to levodopa, and psychiatric medications can exacerbate motor symptoms. Dr. Flaherty advises how to choose the right treatment in patients with parkinsonism accompanied by psychosis, apathy, anxiety, and depression.